DermaSensor vs OpenEvidence
OpenEvidence is free to NPI-verified physicians and funded by advertising. DermaSensor is a rental subscription for a handheld device, with a try-and-return option.
A physician opens OpenEvidence for cited answers from the literature, and the vendor's security page states SOC 2 Type II and HIPAA compliance with a BAA. A primary care practice rents DermaSensor for a spectroscopy reading on a lesion already judged suspicious. The vendor says its result should not be used as the sole diagnostic criterion and is not a screening tool.
Published studies that include OpenEvidence cover a comparison of AI tools on diagnostic radiology board-style questions and a content analysis of how AI tools cite retracted literature. DermaSensor's evidence page lists a vendor-run multi-reader study and a prospective UPMC evaluation with specificity of 9.4% at the lowest cut point.
Decision support · Reviewed November 2, 2026
DermaSensor
by DermaSensor · founded 2009
Handheld spectroscopy device giving primary care physicians an AI score on skin lesions already judged suspicious.
OpenEvidence
by OpenEvidence · founded 2022
Free physician-only literature-grounded Q&A, 1M consults/day.
When to pick each one
DermaSensor
- Handheld spectroscopy score on suspicious lesions
- Try-and-return option on the rental
OpenEvidence
- Free, cited answers for NPI-verified physicians
- SOC 2 Type II and HIPAA with a BAA
Score
Each row shows points earned of points available under the published rubric.
DermaSensor
49of 100
OpenEvidence
52of 100
| Dimension | DermaSensor | OpenEvidence | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 0 / 12 | +12 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 5.6 | 0 / 5.6 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4.8 | 0 / 4.8 | 0 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 21 / 21 | -6.3 |
| RCT / meta-analysis / systematic review | 4.5 / 9 | 4.5 / 9 | 0 |
| Funding & adoption signal | 3 / 12 | 12 / 12 | -9 |
| Pricing transparency | 1.3 / 2.5 | 2.5 / 2.5 | -1.2 |
| Years in market | 6 / 6 | 4.2 / 6 | +1.8 |
Scroll horizontally to see every column.
Pricing
DermaSensor
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No published price for an outright purchase. Monthly rental subscription, one-year device use agreement with try-and-return option. |
OpenEvidence
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Plan | n/a | n/a | Free for NPI-verified physicians (ad-funded). |
Evidence
DermaSensor
FDA decisions
DEN230008 (opens in new tab)De Novo2024-01-12
DermaSensor
Peer-reviewed
3 PubMed records name DermaSensor.
- Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA. (opens in new tab)
- Enhancing Diagnostic Precision in Primary Care: A Multireader Multicase (MRMC) Study of an AI-Powered Handheld Elastic Scattering Spectroscopy Device for Informed Referral Decisions in Melanoma Evaluation. (opens in new tab)
- Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer. (opens in new tab)
OpenEvidence
FDA decisions
No FDA decision cited in our research as of October 20, 2026.
Peer-reviewed
5 PubMed records name OpenEvidence.
- Performance of Large Language Models on Diagnostic Radiology Board-Style Questions: A Comparative Evaluation of GPT-4o, Perplexity AI, and OpenEvidence. (opens in new tab)
- OpenEvidence. (opens in new tab)
- Concordance of ChatGPT, Gemini, Claude, and OpenEvidence with the 2024 AAOS guidelines on acute isolated meniscal pathology. (opens in new tab)
Community
20 posts sourced: 3 positive, 14 neutral, 3 negative.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | DermaSensor | OpenEvidence |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2009 | 2022 |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.